Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Enekinragene Inzadenovec (PCRX-201)
Enekinragene Inzadenovec · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part A Dose A | EXPERIMENTAL | Single Intra-Articular injection |
| Part A, Placebo | PLACEBO_COMPARATOR | Single Intra-Articular injection |
| Part B Dose A | EXPERIMENTAL | Single Intra-Articular injection |
| Part B Dose B | EXPERIMENTAL | Single Intra-Articular injection |
| Part B Placebo | PLACEBO_COMPARATOR | Part B Placebo |
| Part A, Dose B | EXPERIMENTAL | Single Intra-Articular injection |
| Name | Type | Description |
|---|---|---|
| Enekinragene Inzadenovec (PCRX-201) | BIOLOGICAL | Enekinragene Inzadenovec (PCRX-201) injection |
| Placebo | BIOLOGICAL | Placebo injection |
Inclusion Criteria: * Subjects must be willing and able to comply with the study procedures and visit schedule and able to follow verbal and written instructions. * Subjects must be male or female and 45 to 80 years old, inclusive, at Screening. * Subjects must exhibit symptoms associated with oste...
Top 5 of 14 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 4 | PHASE3 | Orforglipron, Eloralintide, LY3016859, LY3556050, LY3526318 |
| Pacira Biosciences, Inc. | PCRX | 4 | PHASE3 | ZILRETTA, Enekinragene Inzadenovec, FX201 |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 2 | PHASE3 | NNC0487-0111 |
| Bioventus, Inc. Class A | BVS | 1 | PHASE2 | PTP-001 |
| Enlivex Ltd. | ENLV | 2 | PHASE1 | Allocetra |
Enekinragene Inzadenovec is an investigational gene therapy being developed for the treatment of painful osteoarthritis of the knee. It is designed to be given to patients with knee osteoarthritis, a musculoskeletal condition. The therapy is currently in Phase 2 clinical development and has not been approved for any use.
Enekinragene Inzadenovec targets IL1RA, the gene for the interleukin-1 receptor antagonist. By delivering this gene, the therapy aims to increase production of the IL1RA protein, which blocks interleukin-1 signaling. This mechanism is intended to reduce inflammation and pain associated with osteoarthritis of the knee. It is a gene therapy modality.
Enekinragene Inzadenovec is being developed by Pacira BioSciences, Inc., which trades on the Nasdaq under the ticker PCRX. Pacira is the sponsor of the clinical program for this gene therapy candidate in knee osteoarthritis.
Enekinragene Inzadenovec is in Phase 2 clinical development. It is an investigational therapy and has not been approved by the FDA or any regulatory agency. The ongoing Phase 2 trial is evaluating the therapy in patients with painful osteoarthritis of the knee.
Enekinragene Inzadenovec is being studied in one active clinical trial, NCT06884865, titled A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the Knee. This Phase 2 trial is currently recruiting and plans to enroll 135 participants in the United States.
Yes, Enekinragene Inzadenovec is also known as PCRX-201. PCRX-201 is the development code used by Pacira BioSciences for this gene therapy candidate. Both names refer to the same investigational product being studied in knee osteoarthritis.